[ABBV] AbbVie Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 62.32 Change: 0.67 (1.08%)
Ext. hours: 62.4 Change: 0.08 (0.13%)

chart ABBV

Refresh chart

Strongest Trends Summary For ABBV

ABBV is in the long-term up 243% in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS4 EPS Growth - 4 Quarters-44.47% EPS Growth - Q/Q-115.9%
EPS Growth - Y/Y Sales Growth - 4 Quarters 2.31% Sales Growth - Q/Q-7.56% P/E17.76
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA6.8% ROE131.88% ROI11.6%
Current Ratio1.39 Quick Ratio1.3 Long Term Debt/Equity2.45 Debt Ratio8.02
Gross Margin79.12% Operating Margin18.33% Net Profit Margin8.89% Dividend Payout Ratio-154.52%
Dividend Yield
Fundamental Data
Cash From Financing Activities-930 M Cash From Investing Activities-873 M Cash From Operating Activities1.59 B Gross Profit4.58 B
Net Profit1.37 B Operating Profit2.11 B Total Assets26.7 B Total Current Assets15.41 B
Total Current Liabilities11.05 B Total Debt15.27 B Total Liabilities25.32 B Total Revenue5.48 B
Technical Data
High 52 week121.94 Low 52 week64.52 Last close99.98 Last change0.75%
RSI36.24 Average true range2.28 Beta1.14 Volume4.37 M
Simple moving average 20 days-2.68% Simple moving average 50 days2.42% Simple moving average 200 days2.97%
Performance Data
Performance Week-2.94% Performance Month0.35% Performance Quart-11.94% Performance Half6.85%
Performance Year50.73% Performance Year-to-date5.21% Volatility daily1.66% Volatility weekly3.7%
Volatility monthly7.59% Volatility yearly26.29% Relative Volume229.33% Average Volume8.94 M
New High New Low

News

2019-06-25 23:17:00 | Replay: What to Watch in The Markets: AbbVie-Allergan, Micron, Buffett, and More

2019-06-25 18:05:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Allergan Plc

2019-06-25 17:33:24 | US Stock Market Overview – Stocks Drop on US/Iran Conflict

2019-06-25 17:33:00 | Surging Allergan Stock Is Approaching AbbVie’s Bid Price

2019-06-25 17:12:00 | The Dow Fell Because the Trump-Xi Meeting May Cover More Than Just Trade

2019-06-25 17:02:00 | What Happened in the Stock Market Today

2019-06-25 16:21:00 | Dow Ends Lower, Stocks Fall as Powell Says Fed 'Grappling' with Rate Cut

2019-06-25 16:15:08 | AbbVie + Allergan: Where Are The Synergies?

2019-06-25 16:10:43 | Pharma Buying Spree Continues As AbbVie Takes Out Allergan For $63 Billion

2019-06-25 16:05:22 | Abbvie Drops by a Record as Allergan Deal Fails to End Doubts

2019-06-25 15:01:07 | AbbVie ABBV Stock Falls After $63 Billion Allergan Acquisition Announcement

2019-06-25 14:58:17 | Allergan Options Bull Wins Big on AbbVie Buyout Buzz

2019-06-25 14:05:00 | AbbVie Shareholders Will Get No Vote on Purchase of Allergan

2019-06-25 13:58:06 | Allergan Finance, LLC -- Moody's reviews Allergan's Baa3 ratings for upgrade

2019-06-25 12:38:00 | Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

2019-06-25 12:37:51 | AbbVie Buys Allergan for Over $60 Billion

2019-06-25 12:28:00 | Stock Market News: AbbVie Bets Big; Can Microsoft Stay on Top?

2019-06-25 12:23:00 | AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

2019-06-25 12:12:28 | Will David Tepper Be Happy about the AbbVie-Allergan Deal?

2019-06-25 12:10:38 | AbbVie’s $63 Billion Mega Deal Returns Focus to Debt-Fueled M&A

2019-06-24 17:45:09 | AbbVie ABBV Dips More Than Broader Markets: What You Should Know

2019-06-24 09:17:00 | FDA lifts hold on one of AbbVie's trials of venetoclax

2019-06-24 08:45:00 | AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t11;14 Genetic Abnormality

2019-06-24 08:42:12 | Forget Bargain Hunting: Tap 5 Stocks With Rising P/E

2019-06-21 17:36:09 | Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

2019-06-21 11:21:03 | Top Ranked Income Stocks to Buy for June 21st

2019-06-21 10:30:02 | Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

2019-06-20 13:45:00 | AbbVie Declares Quarterly Dividend

2019-06-20 09:10:01 | Is AbbVie ABBV a Great Value Stock Right Now?

2019-06-20 07:30:45 | These New Product Launches Could Partially Offset Humira’s Losses

2019-06-19 16:20:02 | What to Look for in AbbVie’s Oncology Portfolio in 2019

2019-06-19 14:50:02 | How Is AbbVie Positioned in June?

2019-06-19 13:19:57 | AbbVie or Allergan: Which Is a Better Pick in June?

2019-06-19 08:00:00 | Is Abbott Laboratories a Buy?

2019-06-19 07:34:09 | How Do Rate Cuts Impact Healthcare Stocks?

2019-06-17 18:13:10 | Bayer to Invest 5 Billion Euros in Weedkiller Research

2019-06-17 17:45:09 | AbbVie ABBV Stock Sinks As Market Gains: What You Should Know

2019-06-17 17:26:09 | J&J's JNJ Tremfya Meets Goal in Psoriatic Arthritis Study

2019-06-17 15:41:07 | Novartis NVS Announces Promising Data on Tasigna & Hyrimoz

2019-06-17 10:25:02 | Top Ranked Income Stocks to Buy for June 17th

2019-06-17 09:15:01 | Why AbbVie ABBV is a Top Dividend Stock for Your Portfolio

2019-06-17 06:00:00 | Why AbbVie Is a Retiree's Dream Stock

2019-06-14 12:06:04 | 3 Big Pharma Stocks to Buy Right Now

2019-06-13 08:24:12 | Pfizer's PFE Xeljanz Effective As Monotherapy in RA Study

2019-06-12 18:00:00 | New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR

2019-06-12 08:15:00 | 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

2019-06-11 15:15:22 | 10 Smart Dividend Stocks for the Rest of the Year

2019-06-11 09:54:01 | Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II

2019-06-11 09:03:01 | Lilly Announces Tradjenta Cardiovascular Outcome Study Data

2019-06-11 07:00:00 | New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ risankizumab Maintains Complete Skin Clearance